bisphosphonates

Bisphosphonates appear to be a current mainstay for the treatment and prevention of the skeletal-related morbidity in cancers.

Concomitant use of bisphosphonates and stating did not further reduce the risk.

About 10% of patients with bone metastases eventually develop hypercalcemia, which can be treated with IV bisphosphonates (eg, pamidronate).

We also review the pharmacologic properties of bisphosphonates and their possible role in the pathophysiology of osteonecrosis.

Bisphosphonates may modestly affect clinical disease activity in ankylosing spondylitis.

The Mayo Clinic team provided recommendations for the myeloma patients for whom bisphosphonates are indicated.

Bisphosphonates are prescription medications that, like other drugs, have multiple possible side effects.

Bisphosphonates, which inhibit osteoclasts, alleviate many of the devastating consequences of metastatic bone disease.

A dental examination before patients begin therapy with intravenous bisphosphonates is advisable if possible.

Bisphosphonates is recommended for patients with bone metastases which can reduce the incidence of bone-related events.

Bisphosphonates have become an integral component of the management of cancer patients who are at risk for treatment-induced bone loss.

Bisphosphonates are effective inhibitors of bone remodeling.

Some individuals have harmful side effects with long-term use of bisphosphonates, the current main class of osteoporosis treatment drugs.

Endoscopic examination suggested gastric mucosal damage by NSAID is more serious than that of bisphosphonates.

The remaining 6 percent diagnosed with osteonecrosis of the jaw took oral bisphosphonates.

When taken orally, bisphosphonates are poorly absorbed and have low bioavailability.

Bisphosphonates can now be distinguished based on their molecular and cellular mechanisms of action.

She picked the drugs because of studies in humans that suggest bisphosphonates may help prevent cancer from spreading to the bone.

However, bisphosphonates may play a role in the development of osteonecrosis of the jaws.

Our current understanding is that bisphosphonates may also disrupt the metastatic process and reduce the development of bone lesions.

For the study, researchers recruited about 2, 000 patients from 23 countries who were not taking oral bisphosphonates.

Bisphosphonates have a chemical structure similar to that of pyrophosphate, part of the mineral phase of bone;

Review: bisphosphonates reduce fractures, radiotherapy, and hypercalcaemia and increase time to a first skeletal related event

Clinical efficacy of bisphosphonates in the treatment of postmenopausal osteoporosis

A Synthetic Method of the Bone Resorption Inhibitor Amino-bisphosphonates and Their Sodium Salts

Recent Advances in Research and Reasonable Application of Bisphosphonates

Therapeutic mechanism of bisphosphonates for metastatic tumor of bone

Clinical trial of bisphosphonates in bone metastasis due to solid tumor

Review of the research of bisphosphonates in the management of periodontitis

Effects of bisphosphonates in treatment of women with osteoporosis

Effects of statins and bisphosphonates on femur of ovariectomized rats

Effects of bisphosphonates on proliferation of lung cancer cells in vitro

The Synthesis of Gem-Bisphosphonates with Carboxylic Group

The promising aspects of bisphosphonates for anti-bone tumor effects

Advances in the Clinical Use of the Bisphosphonates